Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.19 EUR -9.52%
Market Cap: 24.8m EUR

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.39 EUR with a low forecast of 0.36 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.36 EUR
91% Upside
Average
Price Target
0.39 EUR
104% Upside
Highest
Price Target
0.42 EUR
121% Upside
Gensight Biologics SA Competitors:
Price Targets
RAPT
Rapt Therapeutics Inc
424% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
40% Upside
005690
Pharmicell Co Ltd
37% Upside
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
0% Upside
IVACC
Intervacc AB
559% Upside
NIOX
Niox Group PLC
22% Upside
BIOPOR
Bioporto A/S
189% Upside
FLUO
Fluoguide AS
168% Upside

Revenue
Forecast

Revenue Estimate
Gensight Biologics SA

The compound annual growth rate of Gensight Biologics SA's revenue for the next 2 years is 75%.

N/A
Past Growth
75%
Estimated Growth
Estimates Accuracy
-55%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-74%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.39 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.39 EUR with a low forecast of 0.36 EUR and a high forecast of 0.42 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
75%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 2 years is 75%.

Back to Top